Abstract: This invention relates to antiviral organic steroid compositions and derivatives thereof; a process of producing the antiviral compositions; and a method for inhibiting viruses utilizing the compositions. More particularly, the compositions are derived from fireflies of the genus, Photinus.

Abstract: 13alpha-alkylgonan-delta.sup.9(11) -5,10 epoxides of the formula ##STR1## in which R is a hydrogen, methyl or ethyl andZ is a ketal or thioketal group effective as a keto-blocking group, are provided by a process wherein a compound of the formula ##STR2## in which R and Z are as defined above, is irradiated with active ultraviolet radiation.

Abstract: Danazol, a known androgen, is used to (1) correct immune abnormalities associated with hemotologic disorders or (2) treating immune disorders associated with depressed T helper cells, in the invention disclosed.

Abstract: A pharmaceutical vehicle used for administering and protecting active substances, in the form of an anhydrous gel and having a viscosity of at least 540 cps, comprising paraffin oil, at least one fatty acid alkyl ester and a polyvinyldimethyl siloxane-type elastomeric silicone, used as a thickener.

Abstract: The invention relates to a process for the preparation of high-purity gamma- and alpha-cyclodextrin starting from a starch substrate of low reducing capacity, partially hydrolysed with alpha-amylase. According to the invention a starch substrate of low reducing capacity partially hydrolysed with alpha-amylase is converted with cyclodextrin glucosyl transferase, after the addition of an aliphatic ketone of the formula R.sub.1 COR.sub.2, in which R.sub.1 and R.sub.2 stand for a straight or branched chained alkyl group having from 1 to 6 carbon atoms, and/or a phenol derivative of the formula R.sub.3 R.sub.4 PheOH, wherein R.sub.3 and R.sub.4 are hydrogen, alkyl having from 1 to 4 carbon atoms, or R.sub.3 and R.sub.4 together form phenyl group, Phe stand for phenyl group, OH is hydroxyl and/or a benzene derivative of the formula R.sub.5 R.sub.6 Phe, wherein R.sub.5 and R.sub.6 are hydrogen, alkyl having from 1 to 4 carbon atoms, or R.sub.5 and R.sub.

Abstract: The keto group at the 7-position of a bile keto acid is stereoselectively reduced to a beta-hydroxy group with hydrogen in the presence of nickel, a base (the quantity of which is at least 0.3 mole for each mole of keto acid), and an alcohol having from 3 to 10 C atoms, selected from the group consisting of secondary alcohols, tertiary alcohols and beta-branched alcohols.

Abstract: A powdery pharmaceutical composition for application to the mucosa of the oral or nasal cavity including: (a) a base selected from the group consisting of lower alkyl ethers of cellulose; (b) a pharmaceutically effective amount of a drug selected from the group consisting of steroid or glycyrrhizic acid type anti-inflammatory agents; and (c) a stabilizer for the drug composed of at least one low irritant solid organic acid selected from the group consisting of saturated higher aliphatic monocarboxylic acids having 12 or more carbon atoms, aliphatic polycarboxylic acid, hydroxy aliphatic polycarboxylic acids, aromatic carboxylic acids, unsaturated lower aliphatic monocarboxylic acids having six or less carbon atoms, and cellulose derivatives having carboxyl group.

Abstract: Treatment of sickle cell disease using danazol.

Abstract: The present invention relates to shampoo compositions comprising at least about 0.1% of a water insoluble anti-inflammatory agent, from about 5% to about 40% of a synthetic surfactant and water.

Abstract: Dehydroepiandrosterone and acceptable salts thereof are utilized for sexual disfunction therapy.

Abstract: This invention provides 1.alpha.,25-dihydroxy-24a,24a-difluoro-24-homovitamin D.sub.3 and a process for its production. This compound has strong vitamin D activity and low toxicity and is useful for preventing and treating calcium pathobolism, osteoporosis, etc.

Abstract: Using cyanohydrin intermediates, 17-keto steroids are transformed to corticoids and 17.alpha.-acyl progesterones.

Abstract: The subject invention relates to a process for preparing lubricated water-soluble vitamin powders. The water-soluble vitamin powders are lubricated by combining them with a lubricant at a temperature sufficient to melt the lubricant. The powders are directly compressible into tablets and are resistant to demixing.

Abstract: Thioesters of ursodeoxycholic acid of the formula: ##STR1## wherein R represents --H, --CH.sub.3 or --COOH, and R.sub.1 represents ##STR2## are useful in the treatment of altered biligenetic functions, lithiasis or dyskinesia of the biliary ducts. The esters are prepared by reacting the mixed anhydride of ursodeoxycholic acid with an alkyl or phenyl chloroformate with the appropriate mercaptan.

Abstract: Descriptions are given of 11.beta.-aryl-estradienes of general formula I ##STR1## where X means an oxygen atom or a hydroxyimino group N.about.OH, where the hydroxy group may be in the syn or anti position,R.sup.1 means a methyl or ethyl groupR.sup.2 means a --C.tbd.C--CH.dbd.CH.sub.2, a --CH.sub.2 --(CH.sub.2).sub.n --Y--R.sup.3 or a --CH.dbd.CH--(CH.sub.2).sub.m --Y--R.sup.3 group,Y standing for an oxygen or sulfur atom, n for numbers 0 or 1, m for numbers 1, 2 or 3 and R.sup.3 for a hydrogen atom, for an alkyl or acyl radical with 1 to 4 carbon atoms respectively,with the proviso that when m stands for 1 and Y for an oxygen atom, R.sup.3 means an alkyl radical with 1 to 4 carbon atoms.The new 11.beta.-aryl-estradienes possess antigestagenic and antiglucocorticoid effects.

Abstract: A composition for in vivo inhibition of aromatase in a mammal, which comprises an in vivo inhibitory amount of a compound having the following general formula: ##STR1## wherein R.sub.1 is hydrogen or C.sub.1-4 acyl, in combination with a pharmaceutically acceptable carrier or diluent thereof.

Abstract: An improved synthetic lung surfactant consists essentially of dipalmitoyl phosphatidyl choline, a C-14 to C-18 fatty alcohol (preferably hexadecanol), and a non-toxic nonionic surface active agent (preferably tyloxapol). The surfactant is prepared in a powdered lyophilized form that can be stored for extended periods at room temperature. The powdered product can be readily reconstituted by simply adding distilled water.

Abstract: The present invention relates to a stabilized plant protecting agent suspension which can be characterized by containing 10 to 60% by weight of one or more active ingredients, 30 to 5% by weight of oily layer, 0 to 10% by weight of emulsifyer, 10 to 20% by weight of conventionally used excipient and water needed to 100% by weight while by increasing solid concentration oil concentration decreases.The invention also provides a process for the preparation of a stabilized plant protecting agent suspension by adding oil and optionally an emulsifyer and/or water containing layer to a suspension of a suitable particle size of the active ingredient and water soluble excipients, such as surfactants, optionally emulsifiers, dispersing agents, viscosity modifying agents, protective colloids and mixing together the suspension layer and the layer containing the oil with a stirrer of great shearing force and optionally adding to the obtained stabilized suspension further excipients, e.g.

Abstract: A method of hormonally treating menopausal (including perimenopausal and post-menopausal) disorders in women, a composition, and a multi-preparation pack therefor. The administrative regimen to which the pack is particularly adapted comprises continuously and uninterruptedly administering a progestogen to a woman while cyclically administering an estrogen by using a repetitive dosage regimen. This regimen calls for administering the estrogen continuously for a period of time between about 20 and about 120 days, followed by terminating administering the estrogen for a period of time between about 3 and about 7 days. Alternatively, both the progestogen and estrogen may be administered for the full treatment period without interruption.

Abstract: The invention relates to new 6- or 7-methylenandrosta-1,4-diene-3,17-diones of the following formula ##STR1## wherein R is hydrogen or fluorine; R.sub.1 is hydrogen or C.sub.1 -C.sub.6 alkyl; R.sub.2 is hydrogen or halogen; one of R.sub.3 and R.sub.4 is .dbd.CH.sub.2 and the other is hydrogen or C.sub.1 -C.sub.4 alkyl, and when R.sub.3 is .dbd.CH.sub.2, at least one of R and R.sub.4 is other than hydrogen; and the symbol ##STR2## represents a double bond and the symbol ##STR3## represents a single bond when R.sub.3 is .dbd.CH.sub.2 or the symbol ##STR4## represents a single bond and the symbol ##STR5## represents a double bond when R.sub.4 is .dbd.CH.sub.2, which are useful in therapy, in particular as anti-cancer agents.